Effect of co-administration of Amantadine and Aspirin on fatigue in patients with multiple sclerosis
Phase 2
- Conditions
- Multiple sclerosisMultiple scerosis.
- Registration Number
- IRCT201112208430N3
- Lead Sponsor
- Kerman Neuroscience Reserch Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Inclusion criteria: Definite diagnosis of multiple sclerosis; age between 20-50 years; disability scour =6 on the extended disability status scale patients; fatigue score =4 on the fatigue severity scale. Exclusion criteria: Patients with current or recent (within 2 months ago) use of medications or allergy to asprin or amantadin.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Fatigue Severity Scale. Timepoint: Before intervention,30 days after intervention,42days after intervention. Method of measurement: Questionnaire.
- Secondary Outcome Measures
Name Time Method